Gainers

• Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's regular session. The company's market cap stands at $7.6 million.
• Agape ATP (NASDAQ:ATPC) shares moved upwards by 53.57% to $3.87. The market value of their outstanding shares is at $2.5 million.
• AtaiBeckley (NASDAQ:ATAI) stock increased by 32.92% to $7.12. The market value of their outstanding shares is at $1.9 billion.
• CareDx (NASDAQ:CDNA) stock increased by 24.6% to $37.07. The company's market cap stands at $1.5 billion.
• CEL-SCI (AMEX:CVM) stock rose 24.18% to $1.43. The market value of their outstanding shares is at $20.0 million.
• China Pharma Holding (AMEX:CPHI) stock moved upwards by 20.45% to $1.32. The company's market cap stands at $44.5 million.

Losers

• Alpha Compute (NASDAQ:ALP) stock declined by 33.5% to $0.21 during Thursday's regular session. The market value of their outstanding shares is at $7.5 million. The company's, FY earnings came out yesterday.
• Senti Biosciences (NASDAQ:SNTI) shares declined by 25.58% to $0.43. The market value of their outstanding shares is at $18.1 million.
• VivoSim Labs (NASDAQ:VIVS) shares decreased by 25.41% to $0.64. The market value of their outstanding shares is at $2.9 million. The company's, Q4 earnings came out 2 days ago.
• Modular Medical (NASDAQ:MODD) stock fell 16.0% to $3.52. The market value of their outstanding shares is at $22.6 million.
• Jaguar Health (NASDAQ:JAGX) stock fell 15.39% to $1.65. The market value of their outstanding shares is at $9.3 million.
• Lakewood-Amedex (NASDAQ:LABT) shares decreased by 14.82% to $2.07. The market value of their outstanding shares is at $4.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.